241 related articles for article (PubMed ID: 22982873)
21. Clinical trials of conjunctive anticoagulant strategies in thrombolysis.
Kleiman NS
Coron Artery Dis; 1996 Jul; 7(7):508-15. PubMed ID: 8913678
[No Abstract] [Full Text] [Related]
22. Clinician update: direct thrombin inhibitors in acute coronary syndromes.
Wykrzykowska JJ; Kathiresan S; Jang IK
J Thromb Thrombolysis; 2003 Feb; 15(1):47-57. PubMed ID: 14574076
[TBL] [Abstract][Full Text] [Related]
23. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
Campbell KR; Mahaffey KW; Lewis BE; Weitz JI; Berkowitz SD; Ohman EM; Califf RM
J Invasive Cardiol; 2000 Dec; 12 Suppl F():14F-9. PubMed ID: 11156729
[No Abstract] [Full Text] [Related]
24. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro.
Xu Y; Wu W; Wang L; Chintala M; Plump AS; Ogletree ML; Chen Z
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):332-8. PubMed ID: 23348428
[TBL] [Abstract][Full Text] [Related]
25. Direct thrombin inhibitors in cardiac disease.
Weitz JI; Bates ER
Cardiovasc Toxicol; 2003; 3(1):13-25. PubMed ID: 12668887
[TBL] [Abstract][Full Text] [Related]
26. Bivalirudin.
Warkentin TE; Greinacher A; Koster A
Thromb Haemost; 2008 May; 99(5):830-9. PubMed ID: 18449412
[TBL] [Abstract][Full Text] [Related]
27. Heparin-induced thrombocytopenia: treatment options and special considerations.
Dager WE; Dougherty JA; Nguyen PH; Militello MA; Smythe MA
Pharmacotherapy; 2007 Apr; 27(4):564-87. PubMed ID: 17381384
[TBL] [Abstract][Full Text] [Related]
28. Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where?
Lincoff AM
Am Heart J; 2003 Oct; 146(4 Suppl):S23-30. PubMed ID: 14564303
[TBL] [Abstract][Full Text] [Related]
29. [Experimental and clinical results with the thrombin inhibitor Argatroban].
Breddin HK
Hamostaseologie; 2002 Aug; 22(3):55-9. PubMed ID: 12215762
[TBL] [Abstract][Full Text] [Related]
30. Peptidomimetic thrombin inhibitors.
Kikelj D
Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):487-91. PubMed ID: 15692265
[TBL] [Abstract][Full Text] [Related]
31. Building a stronger foundation: improved antithrombin therapy with bivalirudin in percutaneous coronary intervention.
Knopf W
J Invasive Cardiol; 2002 Apr; 14 Suppl B():1B. PubMed ID: 11967384
[No Abstract] [Full Text] [Related]
32. Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance.
Verstraete M
Thromb Haemost; 1997 Jul; 78(1):357-63. PubMed ID: 9198179
[No Abstract] [Full Text] [Related]
33. New developments in acute anticoagulation therapy: what improvements over traditional heparin are on the horizon?
Carter CJ
Postgrad Med; 1996 Jun; 99(6):129-36. PubMed ID: 8668626
[TBL] [Abstract][Full Text] [Related]
34. Trends in parenteral direct thrombin inhibitor use in pediatric patients: analysis of a large administrative database.
Moffett BS; Teruya J
Arch Pathol Lab Med; 2014 Sep; 138(9):1229-32. PubMed ID: 25171706
[TBL] [Abstract][Full Text] [Related]
35. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.
Skrupky LP; Smith JR; Deal EN; Arnold H; Hollands JM; Martinez EJ; Micek ST
Pharmacotherapy; 2010 Dec; 30(12):1229-38. PubMed ID: 21114390
[TBL] [Abstract][Full Text] [Related]
36. Direct thrombin inhibitors: pharmacology and clinical relevance.
Kam PC; Kaur N; Thong CL
Anaesthesia; 2005 Jun; 60(6):565-74. PubMed ID: 15918828
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.
Cruz-González I; López-Jiménez R; Perez-Rivera A; Yan BP
Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1483-93. PubMed ID: 22970706
[TBL] [Abstract][Full Text] [Related]
38. Bivalirudin in acute coronary syndromes and percutaneous coronary intervention.
Lee MS; Makkar RR
Rev Cardiovasc Med; 2006; 7 Suppl 3():S27-34. PubMed ID: 17224881
[TBL] [Abstract][Full Text] [Related]
39. Direct thrombin inhibitors fail to reverse the negative effects of heparin on lung growth and function after murine left pneumonectomy.
Tsikis ST; Hirsch TI; Klouda T; Fligor SC; Pan A; Joiner MM; Wang SZ; Quigley M; Devietro A; Mitchell PD; Kishikawa H; Yuan K; Puder M
Am J Physiol Lung Cell Mol Physiol; 2024 Mar; 326(3):L213-L225. PubMed ID: 38113296
[TBL] [Abstract][Full Text] [Related]
40. Development of argatroban, a direct thrombin inhibitor, and its clinical application.
Matsuo T; Koide M; Kario K
Semin Thromb Hemost; 1997; 23(6):517-22. PubMed ID: 9469623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
